What assessment and management should be recommended for a 38‑year‑old patient with persistent abnormal vaginal discharge, markedly elevated Candida parapsilosis, severely depleted Lactobacillus (predominantly L. iners), elevated Ureaplasma parvum, and refractory symptoms despite extended fluconazole and intravaginal boric acid treatment?

{
  "question": "What assessment and management should be recommended for a patient with persistent abnormal vaginal discharge, markedly elevated Candida parapsilosis, severely depleted Lactobacillus (predominantly L. iners), elevated Ureaplasma parvum, and refractory symptoms despite extended fluconazole and intravaginal boric acid treatment? Age: [AGE] years New patient – consultation not yet undertaken. Information below is based on patient correspondence and the NutriPATH Vaginal Microbiome Mapping report supplied prior to consultation. Full medical, gynaecological, medication, hormonal and treatment history remains to be established at initial consultation. Presenting Concern [PATIENT] is seeking assessment for persistent abnormal vaginal discharge and a history of vaginal Candida that has not resolved despite previous treatment. [PATIENT] reports having consulted multiple doctors and gynaecologists over an extended period without resolution of the problem. The predominant ongoing symptom is persistent abnormal vaginal discharge. [PATIENT] specifically reports: No significant vaginal/vulval itching. No burning. No pain. No significant irritation. Persistent abnormal discharge despite previous treatment. [PATIENT] is seeking a clinician experienced in persistent/refractory vaginal symptoms, non-albicans Candida and interpretation of vaginal microbiome testing. Previous Vaginal / Candida History Patient reports a previous conventional vaginal swab was positive for Candida. This result led to treatment with an extended course of fluconazole. The original pathology report is currently unavailable, therefore it is not yet known: Which Candida species was isolated. Whether this was Candida parapsilosis or another Candida species. Whether fungal quantification was performed. Whether antifungal susceptibility testing was performed. Exact fluconazole dose, frequency and duration. Whether there was partial/temporary response during treatment. Patient reports the extended fluconazole treatment did not resolve the persistent discharge. Patient has also previously used intravaginal boric acid, again without resolution. Exact dose, duration and response are not yet known. Further detailed history of previous antifungals, antibiotics and other vaginal treatments is required during consultation. Previous Medical Assessment Patient reports having been assessed by multiple doctors and multiple gynaecologists regarding the ongoing symptoms. Details of previous examinations, diagnoses, investigations and specialist recommendations have not yet been reviewed. Patient reports extensive investigations relating to other health concerns over the past several years. Gastrointestinal / Broader Health History Patient reports severe chronic abdominal bloating. [PATIENT] has been investigating both the gastrointestinal symptoms and persistent vaginal symptoms over approximately the last couple of years and has consulted multiple doctors and naturopaths. [PATIENT] reports having undergone or obtained: Recent blood investigations. Comprehensive stool testing. Hormone / Endo Mapping testing. Further blood tests planned. CT imaging planned in the coming week. The indication for CT imaging and details of the gastrointestinal, pelvic, endocrine and broader medical history are not yet known. No assumption has been made regarding whether the gastrointestinal symptoms are related to the vaginal microbiome findings. NutriPATH Vaginal Microbiome Mapping Overall Findings Current report demonstrates: Vaginal pH: 4.9 – elevated (reference 3.5–4.5). Bacterial vaginosis: Negative. Aerobic vaginitis: Negative. Markedly elevated Candida parapsilosis. Markedly depleted total Lactobacillus. Detectable Lactobacillus essentially represented by low-level Lactobacillus iners. Ureaplasma parvum detected above laboratory reference range. No other significant BV-associated or AV-associated bacterial overgrowth identified on the supplied results. Mycology Candida parapsilosis Candida parapsilosis: 564.76 ×10⁵ CFU/mL – HIGH Laboratory reference: <1.00 ×10⁵ CFU/mL. This represents the major fungal abnormality identified on the current microbiome mapping. Other Candida species tested: Candida albicans: below detection. Candida dubliniensis: below detection. Candida glabrata: below detection. Candida krusei: below detection. Candida lusitaniae: below detection. Candida tropicalis: below detection. Therefore, C. parapsilosis is the only Candida species detected on the current microbiome assay. Clinical significance and relationship to the persistent discharge require correlation with the patient's complete history, previous conventional fungal cultures and previous treatment response. Beneficial Lactobacillus Profile Total Lactobacilli Total Lactobacilli: 0.14 ×10⁶ CFU/mL – LOW Laboratory reference: >1.00 ×10⁶ CFU/mL. Individual species: Lactobacillus iners: 0.14 ×10⁶ CFU/mL – LOW Lactobacillus crispatus: below detection. Lactobacillus gasseri: below detection. Lactobacillus jensenii: below detection. Lactobacillus rhamnosus: below detection. Lactobacillus salivarius: below detection. Lactobacillus vaginalis: below detection. The measurable Lactobacillus population on this assay therefore appears to be almost entirely L. iners, with overall Lactobacillus abundance markedly depleted. There is no detectable L. crispatus on the current assay. BV-Associated Organisms BV reported as negative. Results include: Gardnerella vaginalis: below detection. Atopobium vaginae: below detection. Megasphaera species: below detection. Prevotella species: 0.03 ×10⁵ CFU/mL, within laboratory reference. BVAB2: below detection. Mobiluncus species: below detection. Bacteroides fragilis: below detection. There is therefore no significant BV-associated bacterial overgrowth demonstrated on this report. Aerobic / Opportunistic Organisms Aerobic vaginitis reported as negative. AV-associated organisms: Escherichia coli: below detection. Enterococcus faecalis: below detection. Staphylococcus aureus: below detection. Streptococcus agalactiae (GBS): below detection. Streptococcus dysgalactiae: below detection. Staphylococcus epidermidis: below detection. Other organisms: Klebsiella pneumoniae complex: 0.03 ×10⁵ CFU/mL, within reference. Peptostreptococcus species: 0.02 ×10⁵ CFU/mL, within reference. Other listed vaginal pathogens are below detection. No significant AV-associated bacterial overgrowth is demonstrated by this assay. Urogenital Mollicutes Ureaplasma parvum Ureaplasma parvum: 5.34 ×10⁵ CFU/mL – HIGH Laboratory reference: <1.00 ×10⁵ CFU/mL. Other Mollicutes: Ureaplasma urealyticum: below detection. Mycoplasma hominis: below detection. Mycoplasma genitalium: below detection. The clinical significance of the U. parvum finding has not yet been determined and should not be assumed to represent the cause of symptoms based on PCR detection alone. STI / Viral Panel Not detected on the supplied report: Chlamydia trachomatis. Neisseria gonorrhoeae. Trichomonas vaginalis. Mycoplasma genitalium. HSV-1. HSV-2. Haemophilus ducreyi. Lymphogranuloma venereum. Treponema pallidum. CMV. VZV. Current Clinical Picture Based only on the information currently available, the major objective vaginal microbiome findings are: 1. Very high C. parapsilosis burden. 2. Severe depletion of total Lactobacillus. 3. Residual Lactobacillus population represented predominantly/essentially entirely by low-level L. iners, with L. crispatus below detection. 4. Mildly elevated vaginal pH of 4.9. 5. Elevated U. parvum detection of uncertain clinical significance. 6. No molecular evidence of BV or AV on this report. 7. Persistent abnormal discharge despite previous extended fluconazole and boric acid treatment. Important Information Still Required at Initial Consultation Full clinical assessment required before determining treatment. In particular: Full onset and chronology of vaginal symptoms. Description, colour, consistency, volume and odour of discharge. Continuous versus episodic symptoms. Relationship to menstruation and intercourse. Menstrual cycle regularity and hormonal status. Contraception, including presence/type/duration of any IUD. Pregnancy/TTC/fertility plans. Obstetric and gynaecological history. Findings from previous gynaecological examinations. Previous vaginal swab and fungal culture results where available. Whether C. parapsilosis has previously been conventionally cultured. Previous Candida species. Previous antifungal susceptibility results, if performed. Exact fluconazole regimen and treatment response. Exact boric acid regimen and treatment response. Other antifungal treatments. Previous antibiotic exposure and indications. Current medications and supplements. Current/past probiotics and strains. Diabetes/prediabetes/glucose history. Endocrine/thyroid history. Immune/inflammatory conditions. Relevant medication-associated immunosuppression. Detailed GI history and chronic bloating. Previous GI investigations and diagnoses. Reason for current blood investigations and upcoming CT imaging. Relevant results from stool/hormonal/Endo Mapping investigations if clinically indicated after history. Sexual/partner history. Vaginal/vulval products, washes, lubricants or other potential irritants. Working Approach for Initial Consultation No definitive diagnosis or treatment plan has yet been established. The initial consultation should integrate the patient's clinical history, previous conventional pathology, treatment response, gynaecological history and broader medical history with the current microbiome findings. Particular questions will include whether the markedly elevated C. parapsilosis is clinically responsible for the persistent discharge, whether previous Candida infection was the same species, whether susceptibility testing has previously been undertaken, and what factors may be contributing to the markedly Lactobacillus-depleted vaginal environment. The U. parvum result should be interpreted in clinical context rather than automatically treated. The patient's broader medical/GI investigations should also be reviewed selectively once the underlying indication and clinical history are established. This is currently a pre-consult summary only and should not be interpreted as a final assessment or management plan."
}